FDA nixes Evoke Pharma ’s gastro nasal spray
The FDA has rejected Evoke Pharma’s (NSDQ:EVOK) application for a metoclopramide nasal spray for diabetic women with gastroparesis.
The Solana Beach, Calif. company’s stock price tumbled 40% on the news yesterday that the agency had found dosing inconsistencies in the pivotal pharmacokinetic study for the spray, Gimoti. In an earlier multi-disciplinary letter to the company, the FDA had cited concerns with quality control, dosing, and a lack of information to support sex-based differences in efficacy.
Get the full story on our sister site, Drug Delivery Business.
Source: Mass Device - Category: Medical Devices Authors: Nancy Crotti Tags: Business/Financial News Drug-Device Combinations Food & Drug Administration (FDA) News Well Pharma Pharmaceuticals Regulatory/Compliance Women's Health evokepharma Source Type: news
More News: Diabetes | Endocrinology | Gastroenterology | Medical Devices | Metoclopramide | Pharmaceuticals | Study | Women